Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas.
Quandt Z, Young A, Barlow GL, Smith JA, Kusmartseva I, Dong S, Shapiro MR, Kang JH, Felton JL, Nguyen VQ, Szot G, Hassoun AA, Perdigoto AL, Herold KC, Nolan G, Bollyky PL, Brusko TM, Nakayama M, Cooper S, Anderson MS| | PubMed
Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study.
Liang SI, Quandt Z, Wienke S, Wang J, Gordon S, Barnett RM, Masannat J, Chang K, Espenschied CR, Quinn KJ, Banks KC, Yang E, Connolly JE| | PubMed
Polyfunctional T follicular helper cells drive checkpoint-inhibitor diabetes and are targeted by JAK inhibitor therapy.
Huang NL, Ortega JG, Kimbrell K, Lee J, Scott LN, Peluso EM, Wang SJ, Kao EY, Kim K, Olay J, Nguyen JN, Quandt Z, Angell TE, Su MA, Lechner MG| | PubMed
From Prediction to Prevention: The Intricacies of Islet Autoantibodies in Type 1 Diabetes.
Abstract PS5-05: Late-onset immune toxicity incidence & risk factors in breast cancer: a multi-institutional study.
Saya Jacob, Samantha Fisch, Carolyne Face, Kelly Blum, Madhuri Chengappa, Saliha Chaudhry, Alexis LeVee, Nikita V. Baclig, Andrew Soliman, Laura Huppert, Zoe Quandt, Laura Quintal, Dame Idossa, Michelle Melisko, A. Jo Chien, Mi-Ok Kim, Joanne Mortimer, Kelly McCann, Anne Blaes, Hope S. Rugo| | UCSF Research Profile
The Use of Continuous Glucose Monitoring to Diagnose Stage 2 Type 1 Diabetes.
Mader JK, Wong JC, Freckmann G, Garcia-Tirado J, Hirsch IB, Johnson SB, Kerr D, Kim SH, Lal R, Montaser E, O'Donnell H, Pleus S, Shah VN, Ayers AT, Ho CN, Biester T, Dovc K, Farrokhi F, Fleming A, Gillard P, Heinemann L, López-Díez R, Maahs DM, Mathieu C, Quandt Z, Rami-Merhar B, Wolf W, Klonoff DC| | PubMed
Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study.
Quandt Z, Lucas A, Liang SI, Yang E, Stone S, Fadlullah MZH, Bayless NL, Marr SS, Thompson MA, Padron LJ, Bucktrout S, Butterfield LH, Tan AC, Herold KC, Bluestone JA, Anderson MS, Spencer CN, Young A, Connolly JE| | PubMed
Abstract 2276: Whole exome sequencing of immune-mediated colitis in cancer patients treated with immune checkpoint inhibitors.
Pooja Middha, Zoe Quandt, Karmugi Balaratnam, Eduardo Cardenas, Christina J. Falcon, Princess Margaret Lung Group, Matthew A. Gubens, Scott Huntsman, Khaleeq Khan, Min Li, Christine M. Lovly, Devalben Patel, Luna Jia Zhan, Melinda C. Aldrich, Geoffrey Liu, Adam J. Schoenfeld, Elad Ziv| | UCSF Research Profile
Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease.
Quandt Z, Perdigoto A, Anderson MS, Herold KC| | PubMed
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.
Middha P, Thummalapalli R, Quandt Z, Balaratnam K, Cardenas E, Falcon CJ, Margaret Lung Group P, Gubens MA, Huntsman S, Khan K, Li M, Lovly CM, Patel D, Zhan LJ, Liu G, Aldrich MC, Schoenfeld A, Ziv E| | PubMed
irAE-GPT: Leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets.
Bejan CA, Wang M, Venkateswaran S, Bergmann EA, Hiles L, Xu Y, Chandler GS, Brondfield S, Silverstein J, Wright F, de Dios K, Kim D, Mukherjee E, Krantz MS, Yao L, Johnson DB, Phillips EJ, Balko JM, Mohindra R, Quandt Z| | PubMed
Polyfunctional IL-21+ IFNG+ T follicular helper cells contribute to checkpoint inhibitor diabetes mellitus and can be targeted by JAK inhibitor therapy.
Huang N, Ortega J, Kimbrell K, Lee J, Scott LN, Peluso EM, Wang SJ, Kao E, Kim K, Olay J, Quandt Z, Angell TE, Su MA, Lechner MG| | PubMed
67O Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity.
C.W. Thorball, Z. Quandt, A. Saha, L. Yao, P. Midda, Y. Xu, C.A. Bejan, F. Hodel, A. Stravodimou, E. Shearer-Kang, M. Aldrich, E.J. Philips, G. Liu, A. Schoenfeld, D. Johnson, E. Ziv, J. Fellay, R. Mohindra, J.M. Balko, G.S. Chandler| | UCSF Research Profile
Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response.
Quandt Z, Jacob S, Fadlullah MZH, Wu C, Wu C, Huppert L, Levine LS, Sison P, Tsai KK, Chow M, Kang JH, Hwang J, Lee JC, Oglesby A, Venegas J, Brintz BJ, Tan AC, Anderson MS, Rosenblum MD, Young A, Daud AI| | PubMed
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.
Middha P, Thummalapalli R, Quandt Z, Balaratnam K, Cardenas E, Falcon CJ, Princess Margaret Lung Group, Gubens MA, Huntsman S, Khan K, Li M, Lovly CM, Patel D, Zhan LJ, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E| | PubMed
Association of germline polygenic risk for thyroid autoimmunity with overall survival in the I-SPY2 Trial.
Kirkpatrick B Fergus, Pooja Middha, Zoe Quandt, Yiwey Shieh, Amrita B Basu, Rosalyn Sayaman, Paula R Pohlmann, Douglas Yee, Rebecca Arielle Shatsky, Claudine Isaacs, Michael J. Campbell, Gillian L. Hirst, Lamorna Brown Swigart, Laura van 't Veer, Elad Ziv, Laura Esserman| | UCSF Research Profile
HLA associations with immunotherapy related endocrine toxicity.
Zoe Quandt, Christian Thorball, Pooja Middha, Douglas Buckner Johnson, Cosmin A Bejan, Lydia Yao, Yaomin Xu, Flavia Hodel, Athina Stravodimou, Esther Shearer-Kang, Geoffrey Liu, Melinda C Aldrich, Adam Jacob Schoenfeld, Elad Ziv, Elizabeth J Phillips, Jacques Fellay, Ewa A Bergmann, G Scott Chandler, Justin M Balko, Ashis Saha| | UCSF Research Profile
Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.
Rita Nanda, Ronald Cohen, Zoe Quandt, Amrita B Basu, Christina Yau, Amy Jo Chien, Lajos Pusztai, Hyo S. Han, Erica Michelle Stringer-Reasor, Claudine Isaacs, Dawn L. Hershman, Rebecca Arielle Shatsky, Jane Perlmutter, Douglas Yee, Angela DeMichele, Laura van 't Veer, Nola Hylton, Laura Esserman, Hope S. Rugo| | UCSF Research Profile
Abstract PS14-03: Delayed and post-treatment immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.
Saya Jacob, Samantha Fisch, Carolyn Face, Laura Huppert, Zoe Quandt, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Anne Blaes, Hope Rugo| | UCSF Research Profile
Outcomes and Adverse Events in Patients with Cancer after Diagnosis of Immunotherapy-Associated Diabetes Mellitus: A Retrospective Cohort Study.
Duvalyan E, Brondfield S, Rushakoff RJ, Anderson MS, Quandt Z| | PubMed
Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency.
Johnson MB, Ogishi M, Domingo-Vila C, De Franco E, Wakeling MN, Imane Z, Resnick B, Williams E, Galão RP, Caswell R, Russ-Silsby J, Seeleuthner Y, Rinchai D, Fagniez I, Benson B, Dufort MJ, Speake C, Smithmyer ME, Hudson M, Dobbs R, EXE-T1D consortium, Quandt Z, Hattersley AT, Zhang P, Boisson-Dupuis S, Anderson MS, Casanova JL, Tree TI, Oram RA| | PubMed
Middha P, Thummalapalli R, Betti MJ, Yao L, Quandt Z, Balaratnam K, Bejan CA, Cardenas E, Falcon CJ, Faleck DM, Princess Margaret Lung Group, Gubens MA, Huntsman S, Johnson DB, Kachuri L, Khan K, Li M, Lovly CM, Murray MH, Patel D, Werking K, Xu Y, Zhan LJ, Balko JM, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E| | PubMed
Abstract 3460: Predicting cessation of immune checkpoint inhibitor therapy due to severe adverse events with an integrated autoimmune disease polygenic risk score.
Pooja Middha, Rohit Thummalapalli, Zoe Quandt, Princess Margaret Lung Group, Matthew A. Gubens, Christine M. Lovly, Geoffrey Liu, Melinda C. Aldrich, Adam J. Schoenfeld, Elad Ziv| | UCSF Research Profile
Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.
Gallagher EJ, Moore H, Lacouture ME, Dent SF, Farooki A, Goncalves MD, Isaacs C, Johnston A, Juric D, Quandt Z, Spring L, Berman B, Decker M, Hortobagyi GN, Kaffenberger BH, Kwong BY, Pluard T, Rao R, Schwartzberg L, Broder MS| | PubMed
Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
Hilder R, Tsai K, Quandt Z, Isaacs D, Drakaki A, Xing Y, In GK, Angell TE, Lechner MG| | PubMed
Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors.
Silverstein J, Wright F, Wang M, Young A, Kim D, De Dios K, Brondfield S, Quandt Z| | PubMed
Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.
Saya Jacob, Zoe Quandt, Michelle E. Melisko, Melanie Majure, Amy Jo Chien, Anne Hudson Blaes, Diane Heditsian, Laura Esserman, Hope S. Rugo| | UCSF Research Profile
The cognitive load of inpatient consults involving immune-related adverse events.
Sam Brondfield, Jordyn Silverstein, Kimberly de Dios, Zoe Quandt| | UCSF Research Profile
Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis.
Quandt Z, Kim S, Villanueva-Meyer J, Coupe C, Young A, Kang JH, Yazdany J, Schmajuk G, Rush S, Ziv E, Perdigoto AL, Herold K, Lechner MG, Su MA, Tyrrell JB, Bluestone J, Anderson M, Masharani U| | PubMed
Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression.
Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy.
Mandel-Brehm C, Vazquez SE, Liverman C, Cheng M, Quandt Z, Kung AF, Parent A, Miao B, Disse E, Cugnet-Anceau C, Dalle S, Orlova E, Frolova E, Alba D, Michels A, Oftedal BE, Lionakis MS, Husebye ES, Agarwal AK, Li X, Zhu C, Li Q, Oral E, Brown R, Anderson MS, Garg A, DeRisi JL| | PubMed
Autoantibody discovery across monogenic, acquired, and COVID-19-associated autoimmunity with scalable PhIP-seq.
Vazquez SE, Mann SA, Bodansky A, Kung AF, Quandt Z, Ferré EMN, Landegren N, Eriksson D, Bastard P, Zhang SY, Liu J, Mitchell A, Proekt I, Yu D, Mandel-Brehm C, Wang CY, Miao B, Sowa G, Zorn K, Chan AY, Tagi VM, Shimizu C, Tremoulet A, Lynch K, Wilson MR, Kämpe O, Dobbs K, Delmonte OM, Bacchetta R, Notarangelo LD, Burns JC, Casanova JL, Lionakis MS, Torgerson TR, Anderson MS, DeRisi JL| | PubMed
Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).
Emily J. Gallagher, Heather Moore, Mario E. Lacouture, Susan Faye Dent, Azeez Farooki, Marcus D. Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura Spring, Brian Berman, Melanie Decker, Gabriel N. Hortobagyi, Benjamin Kaffenberger, Bernice Y. Kwong, Timothy J. Pluard, Ruta D. Rao, Lee S. Schwartzberg, Michael S. Broder| | UCSF Research Profile
Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes.
Perdigoto AL, Deng S, Du KC, Kuchroo M, Burkhardt DB, Tong A, Israel G, Robert ME, Weisberg SP, Kirkiles-Smith N, Stamatouli AM, Kluger HM, Quandt Z, Young A, Yang ML, Mamula MJ, Pober JS, Anderson MS, Krishnaswamy S, Herold KC| | PubMed
189-OR: Immune-Profiling of Pancreatic Tissue Affected by Immune Checkpoint Inhibitor–Induced Diabetes (CPI-D).
ZOE QUANDT, ARABELLA YOUNG, GRAHAM BARLOW, SHEN DONG, JENNIFER SMITH, IRINA KUSMARTSEVA, TODD M. BRUSKO, STEWART COOPER, MARK S. ANDERSON| | UCSF Research Profile
Evaluating survival following severe immune-related adverse events requiring hospitalization.
Francis Wright, Daniel Myung Kim, Jordyn Silverstein, Michelle Wang, Kimberly de Dios, Arabella Young, Zoe E. Quandt, Sam Brondfield| | UCSF Research Profile
Immune checkpoint inhibitor–induced diabetes mellitus across NCI trials.
Zoe E. Quandt, Vanessa Hill, Joe E. Dib, Jason Burian, Sapir Tessler, Abdul Rafeh Naqash, Mark S Anderson, Megan Othus, Elad Sharon| | UCSF Research Profile
Autoantibody discovery across monogenic, acquired, and COVID19-associated autoimmunity with scalable PhIP-Seq.
Vazquez SE, Mann SA, Bodansky A, Kung AF, Quandt Z, Ferré EMN, Landegren N, Eriksson D, Bastard P, Zhang SY, Liu J, Mitchell A, Mandel-Brehm C, Miao B, Sowa G, Zorn K, Chan AY, Shimizu C, Tremoulet A, Lynch K, Wilson MR, Kampe O, Dobbs K, Delmonte OM, Notarangelo LD, Burns JC, Casanova JL, Lionakis MS, Torgerson TR, Anderson MS, DeRisi JL| | PubMed
Patient-Centered Diabetes Care of Cancer Patients.
Kotwal A, Cheung YM, Cromwell G, Drincic A, Leblebjian H, Quandt Z, Rushakoff RJ, McDonnell ME| | PubMed
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer.
Luo J, Martucci VL, Quandt Z, Groha S, Murray MH, Lovly CM, Rizvi H, Egger JV, Plodkowski AJ, Abu-Akeel M, Schulze I, Merghoub T, Cardenas E, Huntsman S, Li M, Hu D, Gubens MA, Gusev A, Aldrich MC, Hellmann MD, Ziv E| | PubMed
Case 20: Partial ß-Cell Destruction: An Atypical Case of Immune Checkpoint Inhibitor Diabetes.
Zoe Quandt, Paras Mehta, Katy Tsai, Victoria Hsiao, Robert Rushakoff| | UCSF Research Profile
Partial ß-Cell Destruction: An Atypical Case of Immune Checkpoint Inhibitor Diabetes.
Zoe Quandt, Paras Mehta, Katy K. Tsai, Victoria Hsiao, Robert J. Rushakoff| | UCSF Research Profile
Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors.
Quandt Z, Young A, Perdigoto AL, Herold KC, Anderson MS| | PubMed
Breaking β Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapy-Induced Diabetes Mellitus.
Quandt Z, Coupe C, Anderson M, Uihlein A, Young A| | PubMed
Identification of novel, clinically correlated autoantigens in the monogenic autoimmune syndrome APS1 by proteome-wide PhIP-Seq.
Vazquez SE, Ferré EM, Scheel DW, Sunshine S, Miao B, Mandel-Brehm C, Quandt Z, Chan AY, Cheng M, German M, Lionakis M, DeRisi JL, Anderson MS| | PubMed
SAT-418 Finding the Needles in the Haystack: Harnessing the Electronic Health Record to Find Thyroid Immune Related Adverse Events.
Zoe Quandt, Laura Trupin, Michael Evans, Gabriela Schmajuk, Mark Stuart Anderson, Jeff A Bluestone, Yazdany Jinoos| | UCSF Research Profile
SAT-667 Partial Beta-Cell Destruction: An Atypical Case of Immune Checkpoint Inhibitor Diabetes Mellitus.
SUN-298 Spectrum of Imaging in Immune Checkpoint Inhibitor Induced Hypophysitis.
Zoe Quandt, Stephanie Kim, Javier Villanueva-Meyer, Catherine Coupe, J Blake Tyrrell, Jeffery A Bluestone, Mark Stuart Anderson, Umesh Masharani| | UCSF Research Profile
Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes.
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.
Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC| | PubMed
Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses.
Robin Kate Kelley, Emily Mitchell, Spencer Behr, Jimmy Hwang, Bridget Keenan, Sarah E Umetsu, John Dozier Gordan, Andrew H. Ko, Pelin Cinar, Chloe Evelyn Atreya, Katherine Van Loon, Thomas Weber, Zoe Ngo, Zoe E. Quandt, Chienying Liu, Alan P. Venook, Lawrence Fong| | UCSF Research Profile
Phase II trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC).
Robin Kate Kelley, Emily Mitchell, Spencer Behr, Jimmy Hwang, Bridget Keenan, Alexander Cheung, John Dozier Gordan, Andrew H. Ko, Pelin Cinar, Chloe Evelyn Atreya, Katherine Van Loon, Thomas Weber, Zoe Ngo, Zoe E. Quandt, Chienying Liu, Alan P. Venook, Lawrence Fong| | UCSF Research Profile
Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer.
PubMed